Every AAS cycle degrades the lipid panel. The mechanism is not complicated — it is hepatic lipase induction. Androgens up-regulate hepatic lipase expression at the SR-BI receptor pathway; hepatic lipase hydrolyses HDL particles, accelerating their clearance from circulation. LDL rises in parallel because VLDL-remnant clearance via the hepatic LDL receptor slows. The oral-to-injectable gradient is the same gradient that runs through hepatotoxicity — 17α-alkylated orals produce the steepest lipid changes because they deliver the highest hepatocyte exposure per mg. The mechanistic case is documented across pharmacology reviews including Hartgens & Kuipers 2004, Sports Med — the comprehensive 50-year-data-summarising review of athlete AAS effects.
The long-term cardiovascular significance is not theoretical. Kanayama et al. 2018, Mayo Clin Proc reviewed cardiovascular morbidity and mortality patterns in long-term AAS users and identified accelerated atherosclerosis driven by cumulative dyslipidaemia as the dominant mechanism. Baggish et al. 2017, Circulation documented coronary atherosclerosis prevalence in long-term AAS-using weightlifters versus matched non-using controls — the difference was substantial and visible on CAC scoring.
The Markers That Matter — Mechanism and Reference
HDL cholesterol (HDL-C) — adult male reference ≥40 mg/dL per AHA/ACC 2018 cholesterol guideline. Mechanism of HDL-C reduction on AAS: hepatic lipase upregulation accelerates HDL2 → HDL3 → clearance pathway; SR-BI receptor expression increases, accelerating reverse cholesterol transport endpoint clearance. On a moderate testosterone-only protocol, expect HDL to fall 20–40% from baseline. Baseline 55 → cycle 35 is a common trajectory. Oral additions steepen the fall — stanozolol and oxandrolone can reduce HDL by 60–80% per published studies (Glazer 1991, J Am Acad Dermatol reviewed lipid effects of stanozolol and oxandrolone in dermatology and bodybuilding contexts). Recovery: HDL returns toward baseline within 2–6 weeks off-cycle. Back-to-back cycling delays full return.
LDL cholesterol (LDL-C) — reference <100 mg/dL low cardiovascular risk, <70 mg/dL with established risk factors. AAS typically raise LDL 15–30% on cycle. Baseline 95 → cycle 125 is representative. Mechanism: reduced LDL receptor expression in hepatocytes slows clearance of LDL particles and VLDL remnants from circulation.
ApoB (apolipoprotein B-100) — the superior cardiovascular risk marker per Sniderman et al. 2019, JAMA Cardiology consensus statement on ApoB as the dominant atherogenic lipoprotein indicator. Each atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a)) carries exactly one ApoB molecule. ApoB counts particles directly; LDL-C estimates cholesterol mass within particles. When LDL-C and particle count diverge — a pattern common in insulin-resistant, metabolic-syndrome, and AAS-using populations — ApoB predicts plaque progression and cardiovascular events better than LDL-C. Target: <90 mg/dL general population, <70 mg/dL established cardiovascular risk, <65 mg/dL active aggressive cardioprotection.
Triglycerides — reference <150 mg/dL fasting. AAS do not consistently move triglycerides unless diet shifts concurrently. Elevated triglycerides on cycle usually reflect caloric surplus plus alcohol intake or insulin resistance, not direct compound effect.
Lp(a) — lipoprotein little-a — reference <30 mg/dL. Genetically determined by LPA gene LPA-isoform repeats; minimal lifestyle or pharmacological modification. Tsimikas 2017, J Am Coll Cardiol reviewed Lp(a) as an independent atherogenic particle and the genetic basis. Measure once in life. Values >50 mg/dL signal elevated baseline cardiovascular risk independent of any other lipid marker and recalibrate downstream protocol risk calculations — a user with Lp(a) of 80 mg/dL has substantially elevated CV risk floor regardless of how clean the rest of the lipid panel reads.
ApoB:ApoA-I ratio — where available, a clean integrative read on atherogenic vs protective particle balance. <0.7 optimal; >1.0 elevated risk threshold per Walldius & Jungner 2004, J Intern Med AMORIS study (175,000 subjects, 5+ year follow-up).
hsCRP (high-sensitivity C-reactive protein) — inflammation marker; not strictly lipid but tracks atherosclerotic disease activity. Ridker et al. 2002, NEJM JUPITER trial established hsCRP as independent CV risk marker. Worth tracking on long-term AAS protocols; rising trend across cycles is a tell for accelerating subclinical disease.
Compound-by-Compound HDL Impact
From worst to mildest based on published lipid-effect data:
- Oxandrolone: severe. 60–80% HDL reduction in published studies at 20 mg/day × 6 weeks (Sallé et al. 1991, Br J Sports Med).
- Stanozolol: severe, comparable magnitude. The combination of high hepatic lipase induction plus aggressive SHBG suppression amplifies the lipid disturbance.
- Methandrostenolone (Dianabol): moderate-severe. 30–50% HDL reduction at standard dose.
- Trenbolone: moderate-severe. Injectable route does not spare the lipid panel; progestogenic activity and hepatic lipase induction remain. Mauras et al. 1994, J Clin Endocrinol Metab documented similar pattern in 19-nor compound class.
- Testosterone (any ester) at supraphysiological dose: moderate, 20–40% reduction. The Bhasin dose-response data show roughly linear HDL reduction with dose above replacement.
- Nandrolone: mild-moderate.
- Boldenone: mild.
- Methenolone (Primobolan): mild — one of the more lipid-friendly injectable AAS.
- Most peptides (BPC-157, GHRP family, CJC-1295): minimal to none.
- Somatropin (HGH): neutral to slightly favourable; chronic use may modestly improve lipid profile via body composition shift.
Timing the Lipid Panel
Fasted draw, 9–12 hours without food. Alcohol suppression 48–72 hours pre-draw — ethanol acutely raises HDL through ApoA-I synthesis stimulation and distorts baseline. Draw cadence:
- Pre-cycle baseline: establishes the denominator.
- Week 5–6 on-cycle: peak compound exposure point. Highest-yield clinical decision moment — HDL below 20 mg/dL at this timepoint shifts the cost-benefit calculation for extending the cycle, and early termination is defensible.
- Week 6–8 post-PCT: recovery validation.
Mitigation — Evidence Base in Leverage Order
Zone-2 cardio, 150+ minutes/week. The most reliable HDL-preserving intervention in both the AAS literature and general cardiology. Mechanism: increased skeletal-muscle lipoprotein lipase activity preserves HDL particle turnover. Documented in Kraus et al. 2002, NEJM STRRIDE trial across exercise dose-response.
Omega-3 (EPA/DHA) 2–4 g/day. Modest HDL preservation, reliable triglyceride reduction. Bhatt et al. 2019, NEJM REDUCE-IT trial — pharmaceutical-grade icosapent ethyl (Vascepa) at 4 g/day demonstrated 25% reduction in major adverse cardiovascular events. Over-the-counter fish oil shows biomarker benefit with weaker outcome data.
Dietary fibre 30+ g/day. Bile-acid binding drives hepatic cholesterol utilisation, modestly improving LDL. Soluble fibre (oat β-glucan, psyllium) shows the strongest effect.
Plant sterols 2 g/day. Reduce intestinal cholesterol absorption ~10%. Compounds like phytosterol-fortified margarine produce modest LDL reduction; clinical value modest but additive.
Statin co-administration in higher-risk users: the contentious question. Kanayama 2018 and increasing AAS-cardiology literature suggest that long-term users with elevated baseline ApoB or family history should consider preventive statin therapy regardless of acute cycle status. The risk-benefit decision warrants clinician discussion; rosuvastatin 5–10 mg has the cleanest tolerability profile in athletes (lower muscle symptom rate than atorvastatin in head-to-head data).
No back-to-back cycling. Repeated cycles without recovery windows compound lipid damage faster than any individual cycle explains. Off-period of minimum 8 weeks for HDL recovery; 12+ weeks for full lipid normalisation.
Baseline HDL <40 mg/dL. Defer oral compounds entirely until baseline is restored. Starting a stanozolol cycle on HDL of 35 produces an on-cycle HDL of 12–18 — a value below which clinically significant cardiovascular events become statistically present in published cohorts.
The Cumulative Concern — Why Single-Cycle Bloodwork Is Insufficient
Atherosclerosis is integrated exposure, not peak exposure. A single cycle with crushed HDL for 12 weeks is not a cardiovascular event — it is a data point. Repeated cycles across a decade, with cumulative time-in-dysfunction at levels that would demand clinical intervention in a non-AAS population, is the pattern that populates the bodybuilder cardiovascular mortality literature.
The Baggish 2017 Circulation cohort is the cleanest demonstration: long-term AAS-using weightlifters showed substantially higher coronary artery plaque burden on cardiac CT versus matched non-using controls, despite acceptable individual lipid panels at the time of imaging. The damage was cumulative across years of cycling and visible only on imaging that single bloodwork cannot replicate.
Coronary Artery Calcium (CAC) scoring is the single most predictive cardiovascular imaging modality for the AAS-using population. Greenland et al. 2018, JACC reviewed CAC’s predictive performance — it outperforms standard risk calculators (Framingham, ACC/AHA pooled cohort) by a wide margin in detecting subclinical atherosclerosis.
Recommended CAC cadence for AAS users:
- Baseline at age 40 for long-term users, age 35 with strong cardiovascular family history.
- Repeat every 5 years if score is 0–10 (low burden).
- Repeat every 2–3 years if score is 11–100 (moderate).
- Refer to cardiology if score >100 (substantial subclinical disease).
- CAC progression rate is more informative than absolute score in younger users.
Lipid management on cycle is not about chasing “normal” numbers per panel. It is about keeping the integrated decade-scale exposure inside a survivable cardiovascular envelope. The users who maintain cardiovascular health on multi-year protocols are the ones who treat lipid panels as longitudinal data series rather than pass-fail snapshots, who run CAC at appropriate intervals, who run preventive statin therapy when the lipid trend demands it, and who accept that some compounds (stanozolol, oxandrolone, oral methylated combinations) carry cardiovascular costs disproportionate to their anabolic benefit.